Parallel Advisors, LLC Eagle Pharmaceuticals, Inc. Transaction History

Parallel Advisors, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 May 20, 2024	SELL	$17.74 - $31.87 $1,915 - $3,441	-108 Reduced 86.4%	17 $0
Q2 2023 Aug 04, 2023	SELL	$17.74 - $31.87 $1,915 - $3,441	-108 Reduced 86.4%	17 $0
Q1 2023 May 20, 2024	BUY	$25.06 - $34.09 $3,132 - $4,261	125 New	125 $3,000
Q1 2023 Apr 25, 2023	BUY	$25.06 - $34.09 $1,854 - $2,522	74 Added 145.1%	125 $3,000
Q4 2022 Feb 03, 2023	BUY	$24.98 - $39.77 $74 - $119	3 Added 6.25%	51 $1,000
Q3 2022 Nov 10, 2022	BUY	$26.42 - $47.12 $396 - $706	15 Added 45.45%	48 $1,000
Q2 2022 Aug 01, 2022	SELL	$41.26 - $51.35 $783 - $975	-19 Reduced 36.54%	33 $1,000
Q1 2022 Apr 28, 2022	SELL	$44.58 - $52.6 $1,560 - $1,841	-35 Reduced 40.23%	52 $3,000
Q4 2021 Jan 20, 2022	BUY	$45.82 - $56.9 $2,016 - $2,503	44 Added 102.33%	87 $4,000
Q3 2021 Nov 02, 2021	BUY	$43.79 - $55.78 $744 - $948	17 Added 65.38%	43 $2,000
Q1 2021 Apr 23, 2021	SELL	$40.32 - $50.97 $846 - $1,070	-21 Reduced 44.68%	26 $1,000
Q3 2020 Oct 27, 2020	BUY	$37.02 - $51.28 $1,739 - $2,410	47 New	47 $2,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.